Biomarkers for the clinical evaluation of the cognitively impaired elderly: Amyloid is not enough

Imaging in Medicine

Volumn 4, Issue 3, 2012, Pages 343-357

  McEvoy, Linda K ^a   Brewer, James B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimers disease; amyloid imaging; biomarker; florbetapir; MCI; mild cognitive impairment; MRI; PET

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN[1-42]; FLORBETABEN; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE; FLUTEMETAMOL F 18; TAU PROTEIN;

ALZHEIMER DISEASE; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL PRACTICE; DIFFUSION WEIGHTED IMAGING; GERIATRIC PATIENT; HUMAN; MILD COGNITIVE IMPAIRMENT; NERVE CELL LESION; NERVE DEGENERATION; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; VOLUMETRIC NUCLEAR MAGNETIC RESONANCE IMAGING;

EID: 84862858677     PISSN: 17555191     EISSN: 17555205     Source Type: Journal    
DOI: 10.2217/iim.12.27     Document Type: Review

References (88)

1. Klunk WE, Engler H, Nordberg A et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann. Neurol. 55(3), 306-319 (2004).
2. Rowe CC, Ackerman U, Browne W et al. Imaging of amyloid b in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 7(2), 129-135 (2008).
3. Wong DF, Rosenberg PB, Zhou Y et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J. Nucl. Med. 51(6), 913-920 (2010).
4. Herholz K, Ebmeier K. Clinical amyloid imaging in Alzheimer's disease. Lancet Neurol. 10(7), 667-670 (2011).
5. Department of Economic and Social Affairs. Population Division. World population ageing. United Nations Publications: UN, NY, USA (2001).
6. Vincent GK, Velkoff VA. Current population reports. The next four decades: the older population in the United States: 2010 to 2050. US Department of Commerce, Economics and Statistics Administration, US Census Bureau (2010).
7. Thies W, Bleiler L. 2011 Alzheimer's disease facts and figures. Alzheimers Dement. 7(2), 208-244 (2011).
8. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34(7), 939-944 (1984).
9. Petersen RC. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256(3), 183-194 (2004).
10. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl.) 82(4), 239-259 (1991).
11. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol. Aging 18(4 SUPPL.), S1-S2 (1997).
12. Bennett DA, Schneider JA, Arvanitakis Z et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66(12), 1837-1844 (2006).
13. Price JL, McKeel DW Jr, Buckles VD et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol. Aging 30(7), 1026-1036 (2009).
14. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C. Age, neuropathology, and dementia. N. Engl. J. Med. 360(22), 2302-2309 (2009).
15. Hyman BT, Phelps CH, Beach TG et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 8(1), 1-13 (2012).
16. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297(5580), 353-356 (2002).
17. Jack CR Jr, Knopman DS, Jagust WJ et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9(1), 119-128 (2010).
18. Selkoe DJ. Resolving controversies on the path to Alzheimer's therapeutics. Nat. Med. 17(9), 1060-1065 (2011).
19. Gomez-Isla T, Hollister R, West H et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 41(1), 17-24 (1997).
20. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42(3 Pt 1), 631-639 (1992).
21. Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 70(11), 960-969 (2011).
22. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 10(9), 698-712 (2011).
23. Pimplikar SW, Nixon RA, Robakis NK, Shen J, Tsai LH. Amyloid-independent mechanisms in Alzheimer's disease pathogenesis. J. Neurosci. 30(45), 14946-14954 (2010).
24. Herrup K. Reimagining Alzheimer's disease- an age-based hypothesis. J. Neurosci. 30(50), 16755-16762 (2010).
25. Lee HG, Zhu X, Castellani RJ, Nunomura A, Perry G, Smith MA. Amyloid-b in Alzheimer disease: the null versus the alternate hypotheses. J. Pharmacol. Exp. Ther. 321(3), 823-829 (2007).
26. Johnston H, Boutin H, Allan SM. Assessing the contribution of inflammation in models of Alzheimer's disease. Biochem. Soc. Trans. 39(4), 886-890 (2011).
27. Di Paolo G, Kim TW. Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat. Rev. Neurosci. 12(5), 284-296 (2011).
28. Ittner LM, Gotz J. Amyloid-b and tau- a toxic pas de deux in Alzheimer's disease. Nat. Rev. Neurosci. 12(2), 65-72 (2010).
29. Desikan RS, McEvoy LK, Thompson WK et al. Amyloid-b associated volume loss occurs only in the presence of phospho-tau. Ann. Neurol. 70(4), 657-661 (2011).
30. Whitwell JL, Josephs KA, Murray ME et al. MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology 71(10), 743-749 (2008).
31. Weiner MW, Veitch DP, Aisen PS et al. The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement. 8(1 SUPPL.), S1-S68 (2012).
32. Klunk WE. Amyloid imaging as a biomarker for cerebral b-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol. Aging 32(SUPPL. 1), S20-S36 (2011).
33. Fagan AM, Mintun MA, Shah AR et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol. Med. 1(8-9), 371-380 (2009).
34. Grimmer T, Riemenschneider M, Forstl H et al. b amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. EMBO Mol. Med. 65(11), 927-934 (2009).
35. Fagan AM, Mintun MA, Mach RH et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Ab42 in humans. Ann. Neurol. 59(3), 512-519 (2006).
36. Clark CM, Schneider JA, Bedell BJ et al. Use of florbetapir-PET for imaging b-amyloid pathology. JAMA 305(3), 275-283 (2011).
37. Leinonen V, Alafuzoff I, Aalto S et al. Assessment of b-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh compound B. Arch. Neurol. 65(10), 1304-1309 (2008).
38. Sojkova J, Driscoll I, Iacono D et al. In vivo fibrillar b-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch. Neurol. 68(2), 232-240 (2011).
39. Hampel H, Burger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement. 4(1), 38-48 (2008).
40. Shaw LM, Vanderstichele H, Knapik-Czajka M et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 65(4), 403-413 (2009).
41. Rowe CC, Ng S, Ackermann U et al. Imaging b-amyloid burden in aging and dementia. Neurology 68(20), 1718-1725 (2007).
42. Fleisher AS, Chen K, Liu X et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch. Neurol. 68(11), 1404-1411 (2011).
43. Resnick SM, Sojkova J, Zhou Y et al. Longitudinal cognitive decline is associated with fibrillar amyloid-b measured by [11C] PiB. Neurology 74(10), 807-815 (2010).
44. Fagan AM, Head D, Shah AR et al. Decreased cerebrospinal fluid Ab(42) correlates with brain atrophy in cognitively normal elderly. Ann. Neurol. 65(2), 176-183 (2009).
45. Jagust WJ, Bandy D, Chen K et al. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement. 6(3), 221-229 (2010).
46. Rowe CC, Ellis KA, Rimajova M et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging 31(8), 1275-1283 (2010).
47. Fjell AM, Walhovd KB, Fennema-Notestine C et al. Brain atrophy in healthy aging is related to CSF levels of Ab1-42. Cereb. Cortex 20(9), 2069-2079 (2010).
48. Becker JA, Hedden T, Carmasin J et al. Amyloid-b associated cortical thinning in clinically normal elderly. Ann. Neurol. 69(6), 1032-1042 (2011).
49. Chetelat G, Villemagne VL, Villain N et al. Accelerated cortical atrophy in cognitively normal elderly with high b-amyloid deposition. Neurology 78(7), 477-484 (2012).
50. Desikan RS, McEvoy LK, Thompson WK et al. Amyloid-b-associated clinical decline occurs only in the presence of elevated P-tau. Arch. Neurol. doi:10.1001/archneurol. 2011.3354 (2012) (Epub ahead of print).
51. Rodrigue KM, Kennedy KM, Devous MD Sr et al. b-amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology 78(6), 387-395 (2012).
52. Stern Y. Cognitive reserve. Neuropsychologia 47(10), 2015-2028 (2009).
53. Kramer PL, Xu H, Woltjer RL et al. Alzheimer disease pathology in cognitively healthy elderly: a genome-wide study. Neurobiol. Aging 32(12), 2113-2122 (2011).
54. Morris JC, Roe CM, Grant EA et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch. Neurol. 66(12), 1469-1475 (2009).
55. Okello A, Koivunen J, Edison P et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 73(10), 754-760 (2009).
56. Villemagne VL, Pike KE, Chetelat G et al. Longitudinal assessment of Ab and cognition in aging and Alzheimer disease. Ann. Neurol. 69(1), 181-192 (2011).
57. Jack CR Jr, Wiste HJ, Vemuri P et al. Brain b-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 133(11), 3336-3348 (2010).
58. Mattsson N, Zetterberg H, Hansson O et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302(4), 385-393 (2009).
59. Vemuri P, Wiste HJ, Weigand SD et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 73(4), 294-301 (2009).
60. Heister D, Brewer JB, Magda S, Blennow K, McEvoy LK. Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology 77(17), 1619-1628 (2011).
61. van Rossum IA, Visser PJ, Knol DL et al. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. J. Alzheimers Dis. 29(2), 319-327 (2012).
62. Fennema-Notestine C, Hagler DJ Jr, McEvoy LK et al. Structural MRI biomarkers for preclinical and mild Alzheimer's disease. Hum. Brain Mapp. 30(10), 3238-3253 (2009).
63. Vemuri P, Wiste HJ, Weigand SD et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 73(4), 287-293 (2009).
64. McEvoy LK, Fennema-Notestine C, Roddey JC et al. Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology 251(1), 195-205 (2009).
65. Westman E, Cavallin L, Muehlboeck JS et al. Sensitivity and specificity of medial temporal lobe visual ratings and multivariate regional MRI classification in Alzheimer's disease. PLoS ONE 6(7), e22506 (2011).
66. McEvoy LK, Holland D, Hagler DJ Jr, Fennema-Notestine C, Brewer JB, Dale AM. Mild cognitive impairment: baseline and longitudinal structural MR imaging measures improve predictive prognosis. Radiology 259(3), 834-843 (2011).
67. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5(3), 228-234 (2006).
68. Dubois B, Feldman HH, Jacova C et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6(8), 734-746 (2007).
69. McKhann GM, Knopman DS, Chertkow H et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7(3), 263-269 (2011).
70. Albert MS, Dekosky ST, Dickson D et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association workgroup. Alzheimers Dement. 7, 270-279 (2011).
71. Sperling RA, Aisen PS, Beckett LA et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement. 7, 280-292 (2011).
72. DeCarli C, Frisoni GB, Clark CM et al. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch. Neurol. 64(1), 108-115 (2007).
73. Shen Q, Loewenstein DA, Potter E et al. Volumetric and visual rating of magnetic resonance imaging scans in the diagnosis of amnestic mild cognitive impairment and Alzheimer's disease. Alzheimers Dement. 7(4), e101-e108 (2011).
74. Jack CR Jr, Barkhof F, Bernstein MA et al. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement. 7(4), 474-485.e474 (2011).
75. Fischl B, Van Der Kouwe A, Destrieux C et al. Automatically parcellating the human cerebral cortex. Cereb. Cortex 14(1), 11-22 (2004).
76. Morra JH, Tu Z, Apostolova LG et al. Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Hum. Brain Mapp. 30(9), 2766-2788 (2009).
77. Barnes J, Foster J, Boyes RG et al. A comparison of methods for the automated calculation of volumes and atrophy rates in the hippocampus. Neuroimage 40(4), 1655-1671 (2008).
78. Chupin M, Gerardin E, Cuingnet R et al. Fully automatic hippocampus segmentation and classification in Alzheimer's disease and mild cognitive impairment applied on data from ADNI. Hippocampus 19(6), 579-587 (2009).
79. Brewer JB, Magda S, Airriess C, Smith ME. Fully-automated quantification of regional brain volumes for improved detection of focal atrophy in Alzheimer disease. Am. J. Neuroradiol. 30(3), 578-580 (2009).
80. Brewer JB. Fully-automated volumetric MRI with normative ranges: translation to clinical practice. Behav. Neurol. 21(1), 21-28 (2009).
81. Fischl B, Salat DH, Busa E et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 33(3), 341-355 (2002).
82. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imaging 32(4), 486-510 (2005).
83. Karow DS, McEvoy LK, Fennema-Notestine C et al. Relative capability of MR Imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease. Radiology 256(3), 932-942 (2010).
84. Golde TE, Schneider LS, Koo EH. Anti-Ab therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron 69(2), 203-213 (2011).
85. Sperling RA, Jack CR Jr, Aisen PS. Testing the right target and right drug at the right stage. Sci. Transl. Med. 3(111), 111cm133 (2011).
86. Strozyk D, Blennow K, White LR, Launer LJ. CSF Ab 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60(4), 652-656 (2003).
87. Buerger K, Ewers M, Pirttila T et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129(Pt 11), 3035-3041 (2006).
88. McEvoy LK, Brewer JB. Quantitative structural MRI for early detection of Alzheimer's disease. Expert Rev. Neurother. 10(11), 1675-1688 (2010).